Twist Bioscience Co. (NASDAQ:TWST) COO Sells $496,320.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 10,340 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $496,320.00. Following the transaction, the chief operating officer now directly owns 221,061 shares in the company, valued at approximately $10,610,928. The trade was a 4.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total value of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total transaction of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $296,636.65.

Twist Bioscience Price Performance

Shares of TWST stock opened at $36.89 on Friday. The business’s fifty day moving average price is $43.90 and its 200 day moving average price is $45.91. The firm has a market capitalization of $2.16 billion, a PE ratio of -9.66 and a beta of 1.78. Twist Bioscience Co. has a 1-year low of $18.80 and a 1-year high of $60.90.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on TWST shares. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Barclays decreased their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Robert W. Baird boosted their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. Finally, Evercore ISI increased their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $51.22.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently made changes to their positions in TWST. SageView Advisory Group LLC purchased a new stake in Twist Bioscience during the first quarter worth about $1,144,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Twist Bioscience during the 1st quarter worth approximately $300,000. Sei Investments Co. grew its holdings in shares of Twist Bioscience by 32.7% in the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock worth $7,670,000 after acquiring an additional 55,124 shares during the period. Silvercrest Asset Management Group LLC increased its stake in Twist Bioscience by 38.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock valued at $4,605,000 after purchasing an additional 37,376 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock worth $6,057,000 after purchasing an additional 83,287 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.